Cobimetinib vs Trametinib

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Melanoma

Shared mechanism: MEK1/2 · full Melanoma pipeline

Cobimetinib

Marketed by Roche and partners

Approved in Melanomasmall molecule
Reliable signal

NCT01689519 · Phase 3 · completed

This was a randomized, triple-blind, placebo-controlled trial with 495 participants. Its primary clinical endpoint, progression-free survival, was significantly better with cobimetinib plus vemurafenib than with vemurafenib plus placebo (hazard ratio 0.51, p=0.0001).

Next expected readout: December 2026 · NCT04835805 (registry estimate)

No aligned efficacy figure on record for this race.

Trametinib

Marketed by Novartis and partners

Approved in Melanomasmall molecule
Weak signal

NCT02039947 · Phase 2 · completed

The study was open-label, nonrandomized, and had no comparator arm; all participants received dabrafenib plus trametinib. Although the primary intracranial response result was reported as 45 of 76 participants (59%), the uncontrolled design provides weak evidence for trametinib’s treatment effect.

Next expected readout: February 2027 · NCT04417621 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Melanoma

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

Cobimetinib: registry results are on file for Melanoma, but their comparison mappings are not yet available.

Trametinib: registry results are on file for Melanoma, but their comparison mappings are not yet available.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Cobimetinib's landscape · Trametinib's landscape